Phone: (919)-558-1323

Contact Us | Our Team

About Us

2016 02 DSS modeling team 4Our mission is to help ensure the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury and modeling and simulation. We aim to make drug development more efficient for the pharmaceutical industry by informing key decisions, which will in turn lead to increased availability of vital medicines for the patients who need them.

DILIsym® Modeling Software

The DILIsym® modeling software was developed as a project focused on developing a predictive, mathematical model of drug-induced liver injury (DILI). Out of these efforts arose the DILI-sim Initiative in 2011 (www.dilisym.com). The DILI-sim Initiative is a consortium of life science companies led by DILIsym Services charged with developing a predictive, mathematical model of drug-induced liver injury. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs.

In order to best meet the needs of proprietary work from industry, DILIsym Services, Inc. was incorporated in 2014 and is operated  in Research Triangle Park, North Carolina. DILIsym Services, Inc. is a startup company committed to providing the pharmaceutical industry with the tools, resources and information to efficiently develop safer drug therapies that increase the availability of vital therapeutics for the patients who need them. The DILIsym Services, Inc. expert scientific team engages the client from initial program design through data input and results interpretation.

Our Goals

DILIsym Services, Inc. has the overarching goal of applying the DILIsym® software to improve the safety profiles of therapeutics reaching the market. To achieve this goal, three significant objectives have been developed:

  • Inform and impact the candidate selection process for therapeutic development teams in the preclinical development space as they prioritize the progression of compounds not yet taken into man;
  • Provide information regarding the risk aspect of the risk versus benefit question often debated as large investments are considered to progress compounds from early stage clinical development to later stage, larger trials;
  • Identify and/or substantiate personalized medicine approaches from a safety perspective that may allow therapeutics to reach a majority of the target patient population without harming a few.
paper 1 title